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Abstract
Background: Norovirus (NoV) GII.4 is the most common genotype for norovirus gastroenteritis worldwide. New
variants or subgenotypes are continuously emerging, thus posing a serious threat to child health.
Methods: We compared retrospectively the clinical manifestations and complications of norovirus gastroenteritis in
children from April, 2004 through December, 2012. NoV variants were analyzed to investigate the association of
circulating viral strains with the complications. A modified disease severity score system based on Vesikari score
system was devised and to evaluate disease severity.
Results: Compared to the outbreak in 2004/2005 winter, significant higher incidence of complications in the later
periods are: convulsive disorder (p < 0.001) in 2006/2007 winter gastrointestinal hemorrhage (p = 0.047) and severe
abdominal pain or irritability (p = 0.033) in 2008/09/10 winter; gastrointestinal hemorrhage (p = 0.030), severe
abdominal pain or irritability (p = 0.014), and prominent hyperthermia (fever >39 °C, p = 0.001) in 2011/2012 winter.
GII.4 Den_Haag_2006b, GII.4 2010, GII.4 Sydney 2012, and GII.4 2012b were the predominant strains in the outbreaks
after 2006. By the modified severity score system, severe norovirus disease occurred in 28.5 %, 32 %, 33.3 %, and 30.
2 % of the patients in the four periods. A longer duration of hospitalization (p = 0.02) were found in those with
high score irrespective of the year of admission.
Conclusions: Our study demonstrated NoV outbreaks in northern Taiwan caused by different GII.4 variants that
were associated with specific complications and uncommon clinical presentations. A modified severity score system
first proposed in this study was able to identify severe cases with a longer hospital stay in NoV-infected children.
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Background
Acute gastroenteritis (AGE) is one of the most common
infectious diseases and still a major cause of pediatric
morbidity and mortality worldwide. The two most im-
portant viral agents in children are rotaviruses and
noroviruses [1]. Norovirus (NoV) is genetically classified
into 6 established genogroups (GI-GVI), while tentative
genogroup GVII is proposed, and of which GI, GII, and
GIV cause diseases in humans [2]. NoV GII.4 has
emerged as the predominant genotype causing outbreaks
of AGE worldwide. In multivariate analysis, NoV GII.4
were associated with higher hospitalization and mortality
rates [3]. In the United States and Europe, NoV are re-
sponsible for approximately 50 % of all reported gastro-
enteritis outbreaks [4]. Similar to rotavirus infection, the
main symptoms caused by norovirus infection are diar-
rhea, vomiting, fever, and even severe dehydration that
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needs hospitalization. Complications of norovirus AGE
in children, such as convulsion, severe dehydration, mal-
nutrition, bowel obstruction and even death were spor-
adically reported [5, 6]. Significant clinical features
correlated with different viral strains has been docu-
mented recently, and after implementing rotavirus vac-
cination, norovirus infection has become one of the
most important enteric pathogens threatening human
health [3, 7]. Our recent study showed that in Taiwan
under suboptimal use of rotavirus vaccines, a significant
increase of norovirus infection was observed in the post-
rotavirus vaccine era [8].
Disease severity score system for AGE was estab-
lished previously [9]. The severity score for different
clinical features and complications caused by emer-
ging enteric viruses such as NoV is lacking. The pur-
pose of this study was to investigate the clinical
features and complications with norovirus infection in
hospitalized pediatric patients supposed to have mod-
erate to severe illness, compared to children treated
in the community setting, and furthermore, we pro-
posed a disease scoring system modified from Vesa-
kari score system for evaluation of norovirus disease
with variable severity in hospitalized patients.
Methods
Patient selection and identification of norovial infection
From April of 2004 through December of 2012, pediatric
patients with the diagnosis of AGE hospitalized in the
Division of Pediatric Gastroenterology, Chang Gung
Children’s Hospital (CGCH) were randomly enrolled.
Their fecal specimens were collected in a clean con-
tainer within 3 days of hospitalization with guardian’s in-
formed consent in this study with exclusion of those
with major underlying diseases. Norovirus infection
was confirmed by the detection of NoV using RT-
PCR from fecal specimens of the patients with diar-
rheal disease [10]. The patient enrollment was irre-
spective of age, sex, ethnicity, and hospitalization
wards. The symptoms were determined and docu-
mented in electronic medical records to determine
how patient-reported symptoms were addressed by
clinicians and clinical data of the patients enrolled
were collected retrospectively from the chart records.
These studies were approved by the Institutional Re-
view Board of the Chang Gung Memorial Hospital.
Norovirus genome sequencing and genotyping
Viral nucleic acid extraction from fecal samples was per-
formed using a kit according to the manufacturer’s rec-
ommendations (QIAamp Viral RNA Mini Kit; Qiagen,
Hilden, Germany). The PCR primers and conditions
used for determining NoV genotypes were described
previously [10]. The cDNA products were cloned into a
plasmid (pCR-XL-TOPO® vector; Invitrogen), and the re-
combinant plasmid was transferred into competent
Escherichia coli (Topo® XL PCR Cloning kit; Invitrogen).
The sequences of different PCR products from the same
specimen were used to reconstruct the near-full-length
norovirus genome using the Vector NTi software pack-
age (Invitrogen). The reference genome sequences of
NoV used for comparison were all obtained from the
National Center for Biotechnology Information database
(http://www.ncbi.nlm.nih.gov/).
Complications of norovirus infection
The complication was recognized and defined as the occur-
rence of extraintestinal or unusual presentations of viral
AGE during hospitalization including abdominal pain or ir-
ritability, gastrointestinal (GI) hemorrhage, electrolyte im-
balance (hyponatremia: serum sodium level < 135 mmol/L;
hypokalemia: serum potassium level < 3.5 mmol/L; or
hypochloremia: serum chloride level < 98 mmol/L), prom-
inent hyperthermia (body temperature > 39 °C), convulsive
disorder (upward gaze, loss of consciousness, involuntary
tonic or clonic manifestations), hypotension or hypovol-
emic shock (systolic blood pressure < 70 mmHg),
hypoglycemia (serum sugar level < 70 mg/dL).
Modified score system for severity of norovirus infection
We evaluated the disease severity of norovirus infection
by the Vesikari score system (total score < 7, mild; 7-≦10,
moderate, and >10, severe. total maximum score 20) [9]
and a modified score system based on clinical informa-
tion from the hospitalized patients (Table 1). The modi-
fied severity score system has a 0–24 point numerical
score, including the assessment for the presence of un-
usual clinical features, such as gastrointestinal
hemorrhage (gross bloody stool or occult blood ≧ 2+ in
stool), convulsion, and additional presentations such as
abdominal pain or flatulence and prolonged or high
fever. The modified system has a more simple stratifica-
tion of general AGE symptoms from 3 points to 2 points
hence with a total maximum score of 24. In our 24
points score system, mild degree is as less than 1/3 max-
imum score (8) and severe degree is half score or higher
(12), that is score, < 8, mild; 8-≦11, moderate, and >11
(12 or higher) severe. The differences of the two score
systems are listed in Table 1.
Statistical analysis
The chi-squared test or Fisher’s exact test was applied to
dichotomous variable analysis, and the unpaired-sample
student’s t-test was used for continuous variable analysis.
A p value of < 0.05 was considered statistically signifi-
cant. All the tests were analyzed using SAS system soft-
ware version 8 for Windows.
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Results
Outbreaks of norovirus acute gastroenteritis
During the period from 2004 to 2012, there were 957
hospitalized pediatric patients fulfilled study criteria ini-
tially enrolled. After the exclusion of 11 with bacterial
infection, 7 finally diagnosed as specific disease other
than infections, and 19 with incomplete clinical data col-
lection, a total of 920 pediatric patients were finally en-
rolled. Among them, 207 (22.5 %) were positive for NoV
in their fecal samples by RT-PCR method and 189 after
excluding 18 with mixed infections, including 10 with
rotavirus, 3 with astrovirus, 2 with enteric adenovirus, 1
with sapovirus, 1 with rotavirus and astrovirus, and 1
with Salmonella. The age distridution of the 920 en-
rolled children was 18 day- 247 months old (Mean:
31.6 months, median: 24 months), and of norovirus in-
fection was 1–240 months old (mean 26.7 months, me-
dian: 17 months). Norovirus infection was confirmed in
patients admitted in the four major outbreaks of 2004/
2005 winter, 2006/2007 winter, 2008/09/10 winter, and
2011/2012 winter in 35 (11.6 %), 75 (41.4 %), 36
(15.9 %), and 43 (20.5 %) patients, respectively.
Complications of norovirus infection in different time
periods
Figure 1 and Table 2 demonstrate the complications of
norovirus infection observed in different time periods.
From 2004 to 2005 winter, the most common complica-
tions were electrolyte imbalance (14.3 %) and
hypoglycemia (11.4 %). From 2006 to 2007 winter, the
most common complications were 28 % for convulsive
disorder and 20 % for hypoglycemia. In 2008/09/10 win-
ter, major complications including GI hemorrhage
(22.2 %) and prominent hyperthermia (13.8 %) were ob-
served. In the latest period from 2011 to 2012 winter,
norovirus infection caused prominent hyperthermia
(34.9 %) and GI hemorrhage (23.3 %) of the patients that
were the most common complications.
Table 1 Comparison of Vesikari and modified Vesikari score
systems for acute gastroenteritis












Max. no. vomiting episodes/24 h
1 1 1a
2–4 2
≥ 5 3 2
Duration of vomiting (days)
1 1 1a
2 2
≥ 3 3 2
Fever
< 37.0 °C 0 0
37.1–38.4 °C 1 1
38.5–38.9 °C 2 2
≥ 39 °C 3 3
Dehydration









Duration of fever (days)
0 N/A 0
1–3 N/A 1











Table 1 Comparison of Vesikari and modified Vesikari score
systems for acute gastroenteritis (Continued)
Assessment of abdomen pain or flatulence
None N/A 0
Flatulence N/A 1
Irritability or pain N/A 2
Total Score 20 24
Total score in Vesikari score < 7, mild; 7-≦10, moderate, and >10, severe. In
modified score, < 8, mild; 8-≦11, moderate, and >11, severe
N/A Not assessed
a Max. no. diarrheal stools/24 h ≥ 4; Duration of diarrhea ≥ 5 days; Max. no.
vomiting episodes/24 h ≦ 4; Duration of vomiting ≦ 2 days
b Hydration amount of less than 1.5 fold maintenance
c Hydration amount of more than 1.5 fold maintenance
d Occult blood (≥) 2+ in stool
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Compared to norovirus infection in 2004/2005 win-
ter, significant higher incidence of complications in
the later periods are: in 2006/2007 winter, convulsive
disorder (p < 0.001); in 2008/09/10 winter, GI
hemorrhage (p = 0.047) and severe abdominal pain or
irritability (p = 0.033); in 2011/2012 winter, GI
hemorrhage (p = 0.030), severe abdominal pain or
irritability (p = 0.014), and prominent hyperthermia
(fever >39 °C) (p = 0.001).
Circulating NoV strains and complications
According to the genomic analysis of NoV, GII.4 was the
most common genotype in all time periods; the major
circulating NoV subgenotype or variant in 2006/2007
Fig. 1 Complications in different periods of norovirus outbreaks in northern Taiwan. The total numbers of hospitalized patients with confirmed
norovirus infection during each outbreak are 35 in 2004–2005, 75 in 2006/2007 winter, 36 in 2008/09/10 winter, and 101 in 2011/12 winter. The
most common complications are electrolyte imbalance (14.3 %) in 2004/2005 winter, convulsion (28 %) 2006/2007 winter, gastrointestinal (GI)
hemorrhage (22.2 %) 2008/09/10 winter, and high fever (34.9 %) 2011/12 winter
Table 2 Complications and uncommon clinical manifestations of norovirus infection in 2004–2012 in northern Taiwan















Abdominal pain or irritability 22.9 (8) 21.3 (16) 0.937 41.7 (15) 0.033 44.2 (19) 0.014
GI Hemorrhage (gross and occult
blood in stool)
8.6 (3) 14.7 (11) 0.217 22.2 (8) 0.047 23.3 (10) 0.030
Electrolyte imbalance 14.3 (5) 13.3 (10) 0.984 8.5 (3) 0.475 11.6 (5) 0.816
Fever >38 °C 37.1 (13) 36 (27) 0.814 25 (9) 0.208 62.8 (27) 0.015
High fever >39 °C 8.6 (3) 9.3 (7) 0.722 13.8 (5) 0.330 34.9 (15) 0.001
Convulsion 2.9 (1) 28 (21) <0.001 2.8 (1) 0.798 9.3 (4) 0.266
Hypotension 5.7 (2) 6.7 (5) 0.817 5.5 (2) 0.983 4.6 (2) 0.825
Hypoglycemia 11.4 (4) 20 (15) 0.316 8.5 (3) 0.475 6.9 (3) 0.320
Disease severity score > 10 (severe) 22.9 (8) 26.6 (20) 0.604 30.6 (11) 0.403 23.3 (10) 0.943





28 of 70 (40 %)
GII.4 2010,
(New Orleans)
16 of 33 (48.5 %)
GII.4 Sydney,
11 of 37 (29.7 %)
GII.4 2012b,
10 of 37 (27 %)
a Percentage of dominant strains in samples available for sub-genotype analysis
b P-value means statistical results of compariing each item in later year period to those in the earlier years of 2004–2005
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winter, GII.4 Den_Haag_2006b (28 of 70, 40 %), caused
most complications of convulsion (19 of 28, 67.9 %) in
infected children. The major subgenotype in 2008/09/10
winter, GII.4 2010 (New Orleans) (16 in 33, 48.5 %),
caused GI hemorrhage (6, 37.5 %). Furthermore, GII.4
2012 subgenotypes (21 in 37, 56.8 %), the predominat
NoV strains in 2011/2012 winter, caused more high fever
(12, 57.1 %) and GI hemorrhage (7, 33.3 %).
Disease severity assessment by a modified score system
compared to Vesikari score system
With regards to assessment using Vesikari score system,
the overall distribution of patients’ disease severity was
mild (score < 7) in 58 patients (30.6 %), moderate (7 ≦
score ≦ 10) 83 (43.9 %), and severe (score > 10) 49
(25.9 %). The proportions of patients with severe disease
were 22.9 %, 26.6 %, 30.6 %, and 23.3 % in the four pe-
riods, and it was usually lower than 30 % (in 3 of the 4
periods). Hospital stays related to disease severity (me-
dian durations with interquartile ranges) are shown in
Table 3: mild level, 5 (4–5) days; moderate, 4 (3–6) days;
and severe, 4 (4–5) days, with the longest hospitalization
in mild level group (Table 3). Under the assessment by
modified score method (Table 1), the distribution of pa-
tients’ disease severity is mild (score < 8) in 50 (26.5 %),
moderate (8 ≦ score ≦ 11) in 80 (42.3 %), and severe
(score > 11) in 59 (31.2 %). The proportions of severe
status are 28.5 %, 32 %, 33.3 %, and 30.2 % with the
highest found in 2008/09/10 winter. Hospital stay ac-
cording to severity assessed by modified score system
(median durations with interquartile ranges) were: mild
disease, 3 (3–4) days; moderate, 5 (4–6) days; and severe,
5 (4–7) days, with the longest hospitalization in severe
disease group (p = 0.002) (Table 3). A longer duration of
hospitalization (p = 0.02) in those with a high score
under modified Vesikari score system rather than by the
original Vesikari score system was observed.
Discussion
NoV is one of the emerging pathogens causing enteric
infections in humans, and the associated clinical presen-
tations are diverse [11–14]. Other than gastrointestinal
symptoms, norovirus infection is associated with several
extraintestinal or unusual complications, including be-
nign infantile convulsion [5], necrotizing enterocolitis
[15], and exacerbations of inflammatory bowel disease
[16], as well as chronic, serious outcomes in immuno-
compromised patients [17, 18]. Comprehensive genotyp-
ing methods have been applied to monitor the
molecular epidemiology of norovirus infections world-
wide. Association of a given genotype or subgenotype
with the occurrence of complications following
gastroenteritis has been reported: GII.4 Den_-
Haag_2006b subtype caused infantile seizure following
gastroenteritis during 2006–2007 outbreaks in Taiwan
and GII.3 infection caused necrotizing enterocolitis
and neonatal death in a neonatal intensive-care unit
in 1998 in the United States [5, 15]. Although the
specific NoV subgenotypes related to severe infection
and complications was only sporadically reported, the
rapid genetic evolution of NoV is believed to be the
main factor driving the changing clinical manifesta-
tions in the infected patients. On the other hand,
there is an unmet need that we need an objective dis-
ease severity score system specifically for the assess-
ment of the severity of norovirus infection, as the
Vesikari score used in rotavirus vaccine trials [19, 20].
Recently, a modified Vesikari score system for severity
assessment of AGE in children in the emergency de-
partments has been devised [21]. This is a simplified
version of Vesikari score system by the deletion of
dehydration status as a score item. Nevertheless, the
evidence-based guidelines in Europe highlighted that
enteric infectious agent is frequently associated with
dehydration which reflects severity of disease and
should be monitored by established severity score sys-
tems [22]. Complications of AGE and dehydration
usually require aggressive management in norovirus
infection. Thus, the addition of clinical complications
as score items to form a modified system for severity
assessment of norovirus infection is necessary. Based
on this, we constructed such a modified system and
verified its performance in assessing norovirus infec-
tion in different outbreaks in this study. A longer
hospitalization in patients classified into mild severity
in Veskari score system could be due to a prolonged
course of fever, and presence of complications, ab-
dominal pain and flatulence not included in Vesikari
score system. These symptoms may cause poor appe-
tite and delayed recovery of activity that require intra-
venous hydration. Furthermore, a significantly longer
hospital stay in the higher-scored patients was found








Mild 58(30.6 %) 50 (26.5 %) 0.437
Moderate 82 (43.9 %) 80 (42.3 %) 0.582
Severe 49 (25.9 %) 59 (31.2 %) 0.283
Hospitalization (days)
Mild 5 (4 ~ 5)b 3 (3 ~ 4) 0.01
Moderate 4 (3 ~ 6) 5 (4 ~ 6) 0.28
Severe 4 (4 ~ 5) 5 (4 ~ 7) 0.027
a Statistical comparison of disease severity assessed by different score systems
b The mean (interquartile range, 25 % ~ 75 %) of hospitalization days
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as practically expected because it is complication-
weighted. Thus, the newly devised modified score sys-
tem could be a useful tool in clinical practice.
There are several limitations in our study. First of all, our
study enrolled hospitalized children usually having a mod-
erate or severe illness rather than children with mild illness
treated in a community setting. Secondly, with regards to
the NoV subgenotypes, we could only verify the major
strains circulating in each outbreak. Thirdly, although all
the fecal samples were tested for bacterial pathogens and
viruses, and NoV was found the only agent positive in these
specimens, still other pathogens that may be associated
with the clinical manifestations are not included in the
panel. Fourthly, in spite of the presence of the complica-
tions in norovirus AGE, the mechanisms for the occurrence
of such intestinal or extra-intestinal complications remain
to be determined.
Conclusions
Vaccine development for the prevention of norovirus in-
fection is currently under way and a more objective as-
sessment of the infection is of paramount importance
[23–27]. This study demonstrated that different circulat-
ing NoV subgenotypes were associated with different
complications and uncommon presentations in a series
of outbreaks over time in northern Taiwan. The stratifi-
cation of hospitalized patients by assessment of the se-
verity of their disease severity using a modified severity
score system is possible, suggesting that the system is
useful for future outbreak investigation. NoV is a rapidly
evolving virus with the circulating genotypes or subge-
notypes varying over time.
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